ClinicalTrials.gg
RecruitingNCT06223880Updated Jan 23, 2025

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

A Phase 4 interventional study of AXS-05 and Bupropion in Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Recruiting at 40 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by Axsome Therapeutics, Inc. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..

Planned enrollment
3rd of 10
350 · median 320
Started
2023
the only one that year
Phase 4
Only one
of the 10
Registered
8th of 10
by date

Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one is the 3rd largest by planned enrollment, is the only one that started in 2023, is the only one in phase 4, and was the 8th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., or all of them as a file.
02

Study summary

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

Read the detailed description

Eligible subjects will receive open-label AXS-05 during the 10-week open-label treatment period, during which they will be monitored for response and remission. Subjects meeting the response and remission criteria during the open-label period will be randomized (1:1) to the double-blind period to continue treatment with AXS-05 or switch to treatment with bupropion (105 mg) tablets. Randomized subjects will receive double-blind treatment for 26 weeks or until they experience a relapse.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • AXS-05
  • Dextromethorphan
  • Bupropion
  • MDD
  • Depression
  • Relapse of depressive symptoms
  • NMDA receptor antagonist
  • Sigma-1 receptor agonist
  • Norepinephrine reuptake inhibitor
  • Dopamine reuptake inhibitor
  • Axsome Therapeutics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meets criteria for diagnosis of MDD without psychotic features
  • Current major depressive episode of at least 4 weeks in duration

Exclusion criteria

Exclusion Criteria:

  • Previously participated in another clinical study of AXS-05; received any drug or device treatment within 30 days of (Screening) Visit 1, or has been prescribed Auvelity.
  • Unable to comply with study procedures
  • Medically inappropriate for study participation in the opinion of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    AXS-05

    AXS-05 tablets, taken twice daily

    Drug: AXS-05

  • Active comparator
    Bupropion

    Bupropion tablets, taken twice daily

    Drug: Bupropion

Interventions

  • DrugAXS-05

    Up to 10 weeks in open-label period; Up to 26 weeks in double-blind period

  • Up to 26 weeks in double-blind period

06

What researchers measure

Primary outcomes

  1. Time from randomization to relapse of depressive symptoms

    Time frame: up to 26 weeks

07

Study locations

40 of 40 sites recruiting
  • Clinical Research Site
    Bellflower, California 90706, United States
    Recruiting
  • Clinical Research Site
    Lafayette, California 94549, United States
    Recruiting
  • Clinical Research Site
    Oceanside, California 92056, United States
    Recruiting
  • Clinical Research Site
    Redlands, California 92374, United States
    Recruiting
  • Clinical Research Site
    Riverside, California 92506, United States
    Recruiting
  • Clinical Research Site
    San Diego, California 92103, United States
    Recruiting
  • Clinical Research Site
    Upland, California 91786, United States
    Recruiting
  • Clinical Research Site
    Brandon, Florida 33511, United States
    Recruiting
  • Clinical Research Site
    Doral, Florida 33122, United States
    Recruiting
  • Clinical Research Site
    Hialeah, Florida 33012, United States
    Recruiting
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
    Recruiting
  • Clinical Research Site
    Miami, Florida 33122, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32801, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32806, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida 32807, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia 30331, United States
    Recruiting
  • Clinical Research Site
    Chicago, Illinois 60634, United States
    Recruiting
  • Clinical Research Site
    Overland Park, Kansas 66210, United States
    Recruiting
  • Clinical Research Site
    New Orleans, Louisiana 70115, United States
    Recruiting
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
    Recruiting
  • Clinical Research Site
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Clinical Research Site
    Las Vegas, Nevada 89102, United States
    Recruiting
  • Clinical Research Site
    Cherry Hill, New Jersey 08002, United States
    Recruiting
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
    Recruiting
  • Clinical Research Site
    Brooklyn, New York 11235, United States
    Recruiting
  • Clinical Research Site
    Mount Kisco, New York 10549, United States
    Recruiting
  • Clinical Research Site
    New York, New York 10128, United States
    Recruiting
  • Clinical Research Site
    Staten Island, New York 10314, United States
    Recruiting
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
    Recruiting
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
    Recruiting
  • Clinical Research Site
    Edmond, Oklahoma 73013, United States
    Recruiting
  • Clinical Research Site
    Oklahoma City, Oklahoma 73118, United States
    Recruiting
  • Clinical Research Site
    Portland, Oregon 97210, United States
    Recruiting
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
    Recruiting
  • Clinical Research Site
    Dallas, Texas 75231, United States
    Recruiting
  • Clinical Research Site
    Dallas, Texas 75243, United States
    Recruiting
  • Clinical Research Site
    Friendswood, Texas 77546, United States
    Recruiting
  • Clinical Research Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Clinical Research Site
    Wichita Falls, Texas 76309, United States
    Recruiting
  • Clinical Research Site
    Everett, Washington 98201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Mar 2026, 27 months after the start.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Jan 25, 2024
StartActual
Dec 27, 2023
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06223880
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Dec 27, 2023
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jan 23, 2025

Study contacts

Study Director
Contact
axs-05-mdd-401@axsome.com
+1 (212) 332-5061

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion